Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $17 from $14 and keeps a Buy rating on the shares. Following the company’s Q3 update, the firm made “incremental positive updates” across its IgAN model following KDIGO guideline revisions ratified in September, partially offset by increased share count, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences Advances Autoimmune Therapies
- Jade Biosciences files to sell 16.13M shares of common stock for holders
- Jade Biosciences Reports Q3 2025 Financial Results
- Jade Biosciences: Promising Pipeline and Strategic Expansion Drive Buy Rating
- Jade Biosciences reports Q3 EPS (48c), consensus (67c)